{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033168","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.514573+00:00","generated_at":"2026-05-30T05:46:35.458697+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed reports Phase 2a biomarker data for neflamapimod in DLB; RewinD-LB topline due Dec 2024","bullets":["Plasma GFAP significantly reduced by neflamapimod (p=0.015 vs placebo); reductions linked to clinical improvement.","RewinD-LB Phase 2b trial fully enrolled; topline data expected December 2024.","Study has >95% statistical power for primary endpoint (CDR-SB) after excluding patients with tau pathology.","DLB affects >1.4M patients in U.S. and EU with no approved treatment, per CervoMed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033168","json":"https://secwatch.observer/filing/0001437749-24-033168.json","markdown":"https://secwatch.observer/filing/0001437749-24-033168.md","text":"https://secwatch.observer/filing/0001437749-24-033168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924033168/0001437749-24-033168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924033168/crvo20241104_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:46:35.458697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}